





(I)

가  
가  
가  
가<sup>5)</sup>  
가  
가<sup>6,7)</sup>  
가

### 3. 항정신병약물의 선택

1 ( )  
가  
1~4  
( )  
5~1 (clozapine augmentation stage) 6  
(combination stage) , 2

### 연구방법

#### 1. 연구대상

DSM - IV 18

5 4

#### 4. 약물치료의 진행

##### 1) 주요임상판단시점 및 항정신병약물의 교체

(Institutional Review Board)

#### 2. 연구자에 대한 교육

19  
21

1~4 5 , 6

##### 2) 연구 기간

2002 10 2003 5

가 20% 가  
 4 가 intent - to - treat( ITT)  
 7 가

3) 중도 탈락

가 Last - Observation - Carried - Forward( LOCF)  
 PANSS, CGI - S, CGI - I ( 4 )  
 가 T (paired T - test)  
 가 (repeated measured ANOVA)

5. 평가 척도

SPSS window 11.0 version , 0.05,

CGI - S(Clinical Global Impression - Severity, CGI - S), CGI - I(Clinical Global Impression - Improvement, CGI - I), PANSS(Positive and Negative Symptom Scale, PANSS)<sup>9)</sup>  
 가 UKU(UKU side effect rating scale, UKU),<sup>10)</sup> LUNSERS(Liverpool University Neuroleptic Side Effect Rating Scale, LUNSERS)<sup>11)</sup>  
 가 DAI - 10(Drug Attitude Inventory - 10, DAI - 10),<sup>12)</sup> PPS(Patient Preference Scale, PPS),<sup>13)</sup> Naber SWN(Subjective Well - being under Neuroleptic treatment, SWN),<sup>14)</sup> WHO - 가 (World Health Organization Quality of Life, WHO - QOL)<sup>15)</sup>  
 가 GAF(Global Assessment of Function, GAF)

6. 분석

PANSS 가

연구 결과

1. 대상 피검자의 일반적 특성 및 과거 병력의 비교

	104	4	108
	53	55	
32.1	70%가		
가	1/4	가	
		70%가	
		9.3%	50.0%
	PANSS	90	
	( 1).		
		22	(20.
4%)			
	8		9
3 , 2			

(l)

## 2. 약물의 선택 및 치료 용량

79% 1  
2, 3, 5  
108 84% 91 7.9%, 5.3%, 7.9% 60%  
가 1 가 가  
(96.9%) 1 1 70%  
2 35.3%, 23.5%, 17.6%

**Table 1.** Demographic and clinical characteristics of enrolled patients

Variables	Patients (n=108)
Age (years)	32.1 ± 8.6
Sex (M : F)	53 : 55
Education (years)	13.4 ± 2.6
Total Numbers of Admission to Psychiatry	3.3 ± 2.9
Diagnosis (Schizophrenia : Schizophreniform disorder)	104 : 4
Age at first treatment for the Psychiatric Symptoms	26.8 ± 7.4
History of previous antipsychotic treatments (%)	70.4%
Duration of previous antipsychotic treatments (years)	2.4 ± 1.3
Used antipsychotics	
Typicals (%)	27.6%
Atypicals (%)	61.9%
Unknown (%)	10.5%
Response with previous antipsychotics	
Response	9.3%
Partial response	50.0%
Non-response	3.7%
Unknown	37%
Current symptom severity	
PANSS	90.4 ± 15.7
CGI-S (7 points)	5.2 ± 1.0

## 3. 치료효과

### 1) PANSS 적도를 통한 약물의 반응정도

가 PANSS 가 20%  
, 75% 54

### 2) 임상적도를 통한 치료 효과


ITT 가 PANSS, CGI - S, CGI - I가  
가 가 PANSS  
가 가 30%  
( 3). 4  
PANSS  
(F=46.9, =0.84, df=2.0, p<0.000)( 1)

**Table 2.** Selected antipsychotics at baseline and dosage of antipsychotics

	Selected antipsychotic (N/%)	Mean of dosage (mg)	Range of dosage (mg)
Risperidone	63 (58.3%)	5.6 ± 1.7	2 - 8
Olanzapine	14 (13.0%)	17.7 ± 5.4	10 - 25
Quetiapine	12 (11.1%)	621.4 ± 197.8	300 - 850
Clozapine	6 ( 5.6%)	505.0 ± 160.5	112.5 - 650
Other atypical antipsychotics	2 ( 1.8%)		
Haloperidol	3 ( 2.8%)	18.3 ± 2.9	
Missing data	8 ( 7.4%)		

**Table 3.** Efficacy of antipsychotic treatments

Scales	Baseline	End points	p value
PANSS (N=72)	89.8 ± 15.6	62.5 ± 22.2	0.000
CGI-S (N=78)	5.3 ± 0.9	2.9 ± 1.3	0.000
CGI-I (N=78)	2.8 ± 1.1	2.1 ± 1.1	0.000
GAF (N=101)	31.3 ± 8.6	61.0 ± 15.0	0.000



**Figure 1.** Changes of PANSS total score in 44 patients who finished antipsychotics treatment for 4 months. \* : Repeated measure one-way ANOVA p<0.05 : PANSS total score significantly decreased compared to 1 CDP for 2 CDP through 4 month (F=46.9, =0.84, df=2.0, p<0.000). CDP : Critical decision point.


CGI - S (F=53.9, =0.88, df=2.0, p<0.000)(  
2)

가 GAF  
(F=

367.2, =1.0, df=1.0, p<0.000).

#### 4. 안정성

가 UKU, LUNSERS  
가 가  
( 10.2, 74.8) 가  
( 8.4, 59.1)가  
(p < 0.05).  
가 가  
가



**Figure 2.** Changes of CGI Severity of illness score in 44 patients who finished antipsychotics treatment for 4 months (n=44) \* : Repeated measure one-way ANOVA p<0.05 : CGI Severity of illness score significantly decreased compared to 1 CDP for 2 CDP through 4 month (F=53.9, =0.88, df=2.0, p<0.000). CDP : Critical decision point.

72  
126 . 가  
52 (41.3%) , 22 (17.5%)  
(11.1%),  
46  
(88.5%) 가 ,  
가 , 2 (9.1%)

#### 5. 약물순응도 및 삶의 질

PPS DAI - 10  
가 가 가  
SWN 46.1 49.3 ,  
WHO - QOL 74.2 79.9  
( 4).

(I)

**Table 4.** Effects of antipsychotic treatment in patient's adherence and quality of life

Category	Scales	Baseline	Endpoint	p value
Patient's compliance	Patient preference scale (N=68)	3.4 ± 1.1	2.3 ± 1.1	0.000
	Drug attitude inventory (N=74)	-0.2 ± 5.3	2.9 ± 4.3	0.000
Quality of life	Subjective well-being (N=59)	46.1 ± 11.7	49.3 ± 7.3	0.024
	WHO-QOL (N=36)	74.2 ± 19.4	79.9 ± 17.1	0.022

## 토 론

2001 가 2003 가 112.5 mg 650 mg

5.6 mg Kwon <sup>16)</sup> 6.5 mg 10 mg 2000 4.98 Cho <sup>17)</sup> 5.66 mg 가

1. 약물의 선택 및 용량

108 84% 60%(63 ) 가 (14 ) (12 ) 100% 가

17.7 mg Kang <sup>18)</sup> 9.7~14.9 mg Lee <sup>19)</sup> Kim <sup>20)</sup> 650 mg 800 mg Cho <sup>17)</sup> 가

2. 치료 효과 및 안정성

32 PANSS 90 가 60%

4 PANSS CGI - S, CGI - I, GAF 가

10 mg 25 mg, 2 mg 8 mg, 30 mg 850 mg PANSS 가 27 ( 30% )

PANSS 가 가 20%  
 54 75% 72 SWN WHO-QOL  
 가 가  
 Lee <sup>21)</sup> 56 8  
 80.5%, 56 92.0%가 27,28)  
 , Lee <sup>22)</sup> 78.6%  
 23) 59% 64% 12 28)  
 Ahn <sup>24)</sup> 69.5% , Kim <sup>29)</sup>  
 50~90% , Kim <sup>30)</sup> PANSS  
 가

**4. 연구의 제한점 및 문제점**

가 2가  
 가 UKU  
 가 LUN-  
 SERS 2가 UKU  
 가 LUNCERS 가  
 가  
 가  
 가 LUNERS <sup>25)</sup> TMAP <sup>4)</sup>  
 가 가

**3. 약물의 순응도 및 삶의 질**

PPS DAI 가 가  
 가  
 DAI 가 가



(l)  
 가 1 84% 91 63%(N=45) 4 75%(N=54)  
 (96.9%)가 1 KMAP

**요 약**

목 적 :

방 법 : 19

108 21

**결 론**

19 108 21  
 가 PANSS CGI , 가 UKU  
 LUNSERS , 가  
 DAI - 10, PPS, Naber SWN, WHO-  
 QOL

PANSS(Positive and Negative Symptom Scale, PANSS) CGI(Clinical Global Impression) , 가 UKU(UKU side effect rating scale, UKU) LUNSERS(Liverpool University neuroleptic side effect rating scale, LUNSERS) ,  
 가 DAI - 10(Drug Attitude Inventory - 10, DAI - 10), PPS(Patient Preference Scale, PPS), Naber SWN(self - rating scale to measure subjective well - being under neuroleptic treatment, SWN), WHO- 가  
 결 과 :

가 PANSS 63%  
 (N=45) 4 75%(N=54)

결 론 :

중심 단어 :

감사문

가 ) : ( ), ( ),  
 ( ), ( ), (가 ),  
 ( ), ( ), ( ),  
 ( ), ( ), ( ),  
 ( ), ( ), ( ),  
 ( ), ( ), ( ),  
 ( ), (가 )

참고 문헌

1) Grimshaw J, Hutchinson A. *Clinical practice guidelines: do they enhance value for money in health care?* Br Med Bull 1995; 51:927-940.

2) Mellman TA, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder SR. *Evidence-Based Pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms.* Psychiatr Serv 2001;52:619-625.

3) Marshall JK. *A critical approach to clinical practice guidelines.* Can J Gastroenterol 2000;14:505-509.

4) Miller AL, Crismon ML, Rush AJ, Chiles J, Kashner TM, Toprac M, et al. *The Texas Medication Algorithm Project: Clinical Results for Schizophrenia.* Schizophr Bull 2004;30:627-647.

5) Ahn YM, Kang DY, Kim SH, Kim CY, Shim JC, An SK, et al. *Designs and methods for the development of Korean medication algorithm for schizophrenic patients.* Korean J Psychopharmacol 2003;14:108-118.

6) Kim BL, Kang YH, Hong KS, Yu BH, S. Peter Kim. *Antipsychotics maintenance therapy of schizophrenic patients-a survey on the psychiatrists' practice in extended Seoul Metropolitan Areas.* J Korean Neuropsychiatr Assoc 1997;36:43-54.

7) Jeong SH, Ahn YM, Kim YS, RODOS Investigator Group in Korea. *The variations in the treatment pattern of schizophrenic patients with risperidone and olanzapine.* J Korean Neuropsychiatr Assoc 2003;42:79-88.

8) Korean Medication Algorithm Project. *The Guideline of Korean Medication Algorithm for Schizophrenia Patients.* Seoul: Jungangmoonhwa;2001.

9) Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. *Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale.* J Korean Neuropsychiatr Assoc 2001;40:1090-1105.

10) Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. *The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side*

*effects in neuroleptic-treated patients.* Acta Psychiatr Scand Suppl 1987;334:1-100.

11) Jung HY, Joo YH, Shin HK, Chung EK, Kang UG, Roh MS, et al. *A Validation Study of Korean-version of Liverpool University Neuroleptic Side Effect Rating Scale(LUNSEERS)-Liverpool University Neuroleptic Side Effect Rating Scale(LUNSEERS).* J Korean Neuropsychiatr Assoc 2002;41:138-145.

12) Hogan TP, Awad AG. *Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.* Psychol Med 1992;22:347-352.

13) Tugwell P. *Patient preference scales.* Agents Actions Suppl. 1985;17:29-31.

14) Naber D. *A self-rating to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables.* Int Clin Psychopharmacol. 1995;10 Suppl 3:133-138.

15) Min SK, Lee CI, Kim KI, Suh SY, Kim DK. *Development of Korean version of WHO Quality of Life Scale Abbreviated version(WHOQOL-BREF).* J Korean Neuropsychiatr Assoc 2000;39:571-579.

16) Kwon JS, Ha TH. *Clinical studies of risperidone in Korea.* Korean J Psychopharmacol 2003;14(Suppl 1):128-139.

17) Cho SJ, Hahn BJ, Suh TW. *Comparison of efficacy and safety between risperidone and quetiapine in schizophrenia and schizoaffective disorder: a pilot study.* Korean J Psychopharmacol 2003;14:215-222.

18) Kang DY, Lee HS. *Clinical studies of olanzapine in Korea.* Korean J Psychopharmacol 2005;16(Suppl 1):23-34.

19) Lee HS, Kim CH, Lee HS, Kim DH, Song DH, Yoo KJ. *Efficacy of long-term treatment with clozapine in refractory schizophrenia patients.* J Korean Neuropsychiatr Assoc 1995;34:700-707.

20) Kim CE, Lee YH, Lee KH, Kang MH. *Clozapine dosage and blood concentrations of Korean adult schizophrenic patients.* J Korean Neuropsychiatr Assoc 2001;40:109-117.

21) Lee MS, Kim YK, Kang BJ, Kim KS, Kim YH, Kim HC, et al. *Efficacy and safety profile of risperidone in schizophrenia: long-term follow-up study.* J Korean Neuropsychiatr Assoc 1999;38:116-127.

22) Lee HS, Kim CH, Jon DI, Jeon JY, Song DH. *Efficacy of long-term treatment with risperidone in treatment-resistant patients with schizophrenia.* Korean J Psychopharmacol 1997; 8:208-217.

23) Suh KH, Lee HS, Cheong HK, Kim KH, Kim BJ, Chang DW, et al. *Comparison of therapeutic effects and side effects between nemonapride and haloperidol treated schizophrenic patients.* Korean J Psychopharmacol 1999;10:40-49.

24) Ahn YM, Kang DY, Kwon JS, Kim CY, Kim CE, Bahn G, et al. *Efficacy and safety of olanzapine in the treatment of Korean patients with schizophrenia and schizophreniform disorder-open multicenter clinical trial.* J Korean Neuropsychiatr Assoc 2001;40:693-707.

25) Guy W. *ECDEU Assessment Manual for Psychopharmacology.* Revised ed, Washington DC, US Department of Health, Education, and Welfare;1976.

26) Voruganti L, Cortese L, Cernovsky Z, Zirul S, Awad A. *Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.* Schizophr Res 2000;43:135-145.

27) Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. *Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization.* Psychiatry Res 1999;86:131-142.

28) Lindstrom LH. *Long-term clinical and social outcome studies*

(l)

- in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994; 380(S):74-76.*
- 29) Kim JH, Yoon JH, Lee, Hee K, Hong SK, Yoon SC, *et al.* Subjective quality of life in schizophrenic patients receiving atypical antipsychotics: relationship to psychopathology, adverse drug effects and subjective response to drug. *J Korean Neuropsychiatr Assoc 2003;42:222-230.*
- 30) Kim EK, Seo KR, Yoon CY. Effect of clozapine on the quality of life in treatment-resistant schizophrenic patients. *Korean Neuropsychiatr Assoc 1999;38:1447-58.*